Experimental Drug “Cures” Hepatitis C

Sun Daily reports that an experimental drug combination cured 70 percent of patients with hepatitis C in early trials, offering hope of a simpler remedy for the chronic liver disease, US researchers said Tuesday.

As quoted in the market news:

The phase II trial described in the Journal of the American Medical Association (JAMA) studied the effectiveness and safety of an experimental drug, sofosbuvir, taken with the licensed antiviral drug ribavirin.

Click here for the full article by Sun Daily